ARKEMA FADES AWAY (BUY; +39% UPSIDE)

03/09/24 -" Portfolio rotation has been a key profitability driver and a crucial aspect of Arkema’s (Buy; France) equity narrative. Its 2028 targets appear to be more of the same, and achieving them becomes ..."

Executive summary
Conflict of interest

Pages

Language

English

Published on

03/09/24

Download

You may also be interested by these reports :

03/09/24

Idea Kicker

Portfolio rotation has been a key profitability driver and a crucial aspect of Arkema’s (Buy; France) equity narrative. Its 2028 targets appear to be ...

29/08/24

BRAIN Biotech AG

Lower guidance end expected – Still ambitious

28/08/24

Arkema

Following the weaker-than-expected Q2 results, we have revised our estimates downward. The global economy remains unstable, with profitability ...

26/08/24

SGL Carbon SE

We have integrated the latest figures and downgraded our 2024 estimates due to the weaker-than-expected Q2 performance which was partly caused by the ...

EXECUTIVE SUMMARY

Updates

Pension Risks

Target & Opinion

Governance & Management

Business & Trends

Graphics : Momentum

Money Making

Graphics : MACD & Volumes

Debt

Graphics : Sensitivities

Valuation

Sector: Performance

DCF

Sector: Key data

NAV/SOTP

Sector: Ratios & Valorisation

Worth knowing

Sector: Peers

Financials

Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking

Trading in corporate shares

Analyst ownership

Advising of corporate (strategy, marketing, debt, etc)

Research paid for by corporate

Provision of corporate access paid for by corporate

Link between and a banking entity

Brokerage activity at AlphaValue